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Abstract
The molecular epidemiology of human papillomavirus (HPV)
infection in a sample of Greek women (n = 2952, mean age
42.2 ± 13.3 years) was examined. HPV prevalence was 50.7%
(95% conﬁdence interval, 48.8–52.6). The most frequent HPV
types were HPV 53, 51 and 66 (10.2%, 9.4% and 9.3%, respec-
tively). HPV positivity was associated with age, age of sexual
debut, number of sexual partners and duration of sexual rela-
tionship, while marriage or multiparity protected against infec-
tion (all p <0.001). Follow-up of this cohort will assist in
predicting the effect of vaccination with the new HPV vaccines
on future screening with HPV-based tests for cervical cancer.
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The effects of the introduction of the two new human papil-
lomavirus (HPV) vaccines in cervical screening programmes
are unknown. Adequate knowledge of the local epidemiology
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of HPV infection together with data on HPV type distribu-
tion in premalignant and malignant lesions is important in this
regard.
We examined the molecular epidemiology of HPV infec-
tion in a large sample of Greek women using a novel molec-
ular technique prior to the implementation of prophylactic
HPV vaccination.
The study evaluated all women consecutively examined
between January 2006 and December 2007 at the outpatient
gynaecological clinics of ten participating hospitals in Greece
(four in southern and six in northern Greece). A structured
questionnaire focusing on demographics, social history and
risk factors known to be associated with HPV infection was
administered to all women prior to the gynaecological evalu-
ation. A liquid-based cytology (ThinPrep Pap-Test) sample
was taken following consent for study participation. A mono-
layer smear was prepared on a TP 2000 Processor and
stained according to the Papanicolaou method. Trained cyt-
opathologists diagnosed each case, according to the Bethesda
classiﬁcation system [1].
The CLART HPV 2 kit (Clinical Array Technology,
Genomica, Madrid, Spain) allowed the detection of up to 35
different HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42,
43, 44, 45, 51, 52, 53, 54, 56, 58, 61, 62, 66, 68, 70, 71, 72,
73, 81, 82, 83, 84, 85 and 89. The diagnostic sensitivity and
speciﬁcity of the CLART HPV 2 kit are 98.2% and 100%,
respectively.
Correlations between cytological ﬁndings and HPV DNA
testing were performed. Logistic regression analyses were
used to identify predictors of HPV positivity (any type vs.
high-risk types (deﬁned according to previous reports [2])
vs. types 16 and 18) and higher grade cytological lesions. The
SPSS software package (version 16, SPSS, Chicago, IL, USA)
was used for the statistical analysis. The research was per-
formed with the approval of the Institutional Review Board
and in compliance with the Helsinki declaration. All partici-
pating women signed an informed consent.
Up to December 2007, 2952 women (mean age
41.9 ± 13.4 years) were examined and 2300 had fully evalu-
able cytology and array results. Six of the ten participating
centres contributed more than 70 patient samples (three
centres from large metropolitan areas contributed more
than 400 patient samples each). Characteristics of the popu-
lation are shown in Table 1. HPV DNA was detected in
1356 of 2676 consecutively evaluated samples (prevalence of
50.7%; 95% conﬁdence interval (CI), 48.8–52.6). The distribu-
tion of positives was similar across centres (range 45.9–
58.6% for the six centres contributing 70 samples or more).
The most frequent HPV types identiﬁed were: HPV 53, 274
positive, prevalence of 10.2% (95% CI: 9.1%–11.5%); HPV 51,
252 positive, prevalence 9.4% (95% CI, 8.4%–10.6%); HPV
66, 249 positive, prevalence of 9.3% (95% CI, 8.2%–10.5%);
HPV 16, 217 positive, prevalence of 8.1%, (95% CI, 7.1%–
9.2%)]; HPV 31, 213, prevalence of 8% (95% CI, 7%–9.1%)];
and HPV 59, 135 positive, prevalence of 5.3% (95% CI,
4.3%–6%). HPV 18 was identiﬁed in 109 women for a preva-
lence of 4.1% (95% CI, 3.4%–4.9%) while HPV types 6
(n = 100) and 11 (n = 27) had a prevalence of 3.7% (95% CI,
3.1–4.5%) and 1% (95% CI, 0.7–1.5%), respectively.
Table 2 depicts rates of HPV positivity by cytological
result. HPV DNA positivity for any HPV type was noted for
39.5% of participating women with normal cytology, while
HPV 16 or 18 positivity was noted in 6.5% of these women.
HPV DNA positivity with any type was seen in 94.4% of
women with High Grade Squamous Intraepithelial Lesion
(HGSIL) cytology lesions (high-risk types 92.6%, Table 2).
The most prevalent HPV types in order of frequency were
types 53, 66, 51, 31 and 39 (normal cytology), types 53, 16,
51, 58, 31 and 66 (Low Grade Squamous Intraepithelial
Lesion (LGSIL)) and types 16, 31, 53, 51, 66 and 18 (HGSIL).
HPV DNA positivity was 100% for cervical cancers diagnosed
by cytology while infection with HPV type 16 was identiﬁed
in ﬁve (50%) out of ten squamous cancers and three out of
six adenocarcinomas diagnosed by cytology. HPV types 45,
TABLE 1. Characteristics of 2592 women with cervical
samples
Age (years)
£21 88 (3.8)
22–30 644 (21.8)
31–45 1091 (37)
46–65 981 (33.2)
>65 148 (5)
Age of sexual debut, mean in years ± SD 19 ± 3
Marriage, n (%), n = 2079 responders 1332 (45.1)
Age of marriage, median (IQR) 21 (18–25)
Duration of marriage, median (IQR) 16 (4–29)
Number of lifetime sexual partners, n (%), n = 2142 responders
0 279 (13)
1 916 (42.8)
2 281 (13.1)
‡3 666 (31.1%)
>6 176 (8.2)
Number of deliveries, n (%), n = 2474 responders
0 916 (37)
1 314 (12.7)
2 801 (32.4)
3 290 (11.7)
>3 153 (6.2)
Number of abortions, n (%), n = 2474 responders
0 1647 (66.6)
1 380 (15.4)
2 249 (10.1)
‡3 198 (8)
History of any sexually transmitted
disease, n (%), n = 619 responders
194 (31.4)
History of warts (ever), n (%), n = 619 responders 170 (27.5)
Ever PAP test, n (%), 1607 (54.4)
Smoking, n (%), n = 2378 responders 890 (24.5)
Smoking, pack-years, median (IQR) 5 (0.1–15)
Alcohol use daily, n (%), n = 2427 responders 34 (1.5)
Alcohol use occasionally, n (%), n = 2118 responders 1079 (44.5)
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51, 52, 53, 58 and 66 and HPV types 33, 39, 45, 53 and 58
were recovered from samples with a diagnosis of squamous
cell cancer or adenocarcinoma, respectively.
HPV DNA positivity was associated with age, age of sex-
ual debut, number of sexual partners and duration of sexual
relationship, while marriage or multiparity protected against
infection (all p <0.001). Age of <30 years old exhibited a
strong association with detection of any of the HPV types 6,
11, 16 or 18 (odds ratio (OR), 1.7; 95% CI, 1.3–2.2;
p <0.001) as well as with each one of these types individually
(p £0.02 for all associations). Having more than six lifetime
sexual partners (OR, 1.7; 95%CI, 1.2–2.4; p 0.004) and a sex-
ual debut before19 years of age (OR, 1.5; 95% CI, 1.2–1.8;
p <0.001) were both associated with higher rates of HPV
DNA infection. The combination of lengthier marriages and
longer times from ﬁrst intercourse was signiﬁcantly associ-
ated with protection from HPV infection (p <0.001).
HPV DNA positivity correlated with both LGSIL (OR, 3.5;
95% CI, 2.6–4.7, p <0.001; and more speciﬁcally HPV types 6,
11, 16, 18, 33, 40, 42, 51, 52, 53, 56, 58, 61, 62, 68, 82 and
84, all p <0.05) and HGSIL (OR, 13.1; 95% CI, 4.1–42.2,
p <0.001; and more speciﬁcally HPV types 16, 18, 31, 33, 52,
53, 59, 68 and 82, all p <0.05). HPV DNA array positivity for
high-risk types correlated with both LGSIL (OR, 2.7; 95% CI,
2.1–3.6; p <0.001) and HGSIL (OR, 13; 95% CI, 4.7–36.1;
p <0.001). Infection with types 16 or 18 correlated with both
LGSIL (OR, 2.3; 95% CI, 1.7–3.1; p <0.001), HGSIL (OR, 11.6;
95% CI, 6.6–20.3; p <0.001) and the diagnosis of squamous
cell Ca (OR, 6.7; 95% CI, 1.9–23.4; p 0.005). High-risk HPV
types as well as infection with HPV types 16 or 18 were asso-
ciated with HGSIL in women over the age of 30 (p <0.001).
High rates of prevalent HPV DNA infection were detected in
this large sample of women in Greece. High-risk HPV types not
covered by the current HPV vaccines were prevalent, with HPV
types 53, 56 and 51 exhibiting the highest frequency. HPV DNA
positivity (including types not directly covered by the circulating
vaccines, but also types 16 and 18) correlated with higher grade
cytological lesions. To our knowledge, this is the largest
reported study so far from our geographical area. Almost identi-
cal high rates of HPV acquisition have been recently described in
a smaller population sample from our country [3]. Our ﬁndings
are not concordant with other reports, especially in the normal
or ASCUS cytology categories [4], indicating a population at high
risk of HPV acquisition. The overall prevalence of HPV type 16
(approximately 8%), the type most often implicated in cervical
carcinogenesis, was low, in concordance with reports from
other geographical areas [2]. Studies evaluating a clinic-based
population rather than a general population are more likely to
overestimate the prevalence of HPV type 16 infections [2,5,6].
Such discrepancies could be explained by variances in the popu-
lation study or differences in the tropism of some HPV phyloge-
netic groups for the genital area [2,5].
The risk factors for HPV positivity identiﬁed in this study
concur with previously reported ﬁndings. Sexual intercourse
remains one of the main factors implicated in HPV transmis-
sion [2,7–9]. The identiﬁcation of various risk factors
associated with HPV infection in this study will lead to better
screening and control programmes in Greece in the near
future.
This study was held in a country where cytological
screening is at best opportunistic, as made evident by
rates of higher grade cytological lesions in the current and
other evaluations [10]. It is likely that we have overesti-
mated the prevalence of disease in speciﬁc subgroups (e.g.
patients from large tertiary care centres, where health-
seeking behaviour is more prevalent, especially in patients
at higher risk of HPV exposure). Furthermore, some of
the centres examined populations from largely under-
served areas. Moreover, cumulative HPV exposure is prob-
ably underestimated as the majority of HPV infections
clear after the initial infection [2,11,12]. In a similar man-
ner, it is well known that the prevalence of any infection
TABLE 2. Cytological diagnosis according to HPV DNA positivity (any type, high-risk types and types 16 and 18) for n = 2300
subjects with available complete cytology and HPV DNA data. Rates are given over row totals. Proportions are given in
brackets
Diagnosis
HPV
DNA (+)
HPV
DNA (+)
HR types
HPV
6
HPV
11
HPV
16
HPV
18
HPV
DNA (+)
types 16
or 18
HPV
DNA
(+) types 6,
11, 16 or 18
Normal cytology, n = 1348 532 (39.5) 461 (34.2) 31 (2.3) 9 (0.7) 54 (4) 39 (2.9) 87 (6.5) 117 (8.7)
ASCUS, n = 560 465 (83) 400 (71.4) 30 (5.4) 7 (1.3) 68 (12.2) 38 (6.8) 99 (17.7) 123 (22)
ASC-H, n = 8 4 (50) 4 (50) 0 (0) 0 (0) 1 (12.5) 0 (0) 1 (12.5) 1 (12.5)
LGSIL, n = 314 252 (80.3) 222 (70.7) 35 (11.1) 10 (3.2) 56 (17.8) 22 (7) 73 (23.2) 100 (31.8)
HGSIL, n = 54 51 (94.4) 50 (92.6) 3 (5.6) 1 (1.9%) 27 (50) 7 (13) 33 (61.1) 34 (63%)
Cervical squamous
carcinoma, n = 10
10 (100) 10 (100) 0 (0) 0 (0) 5 (50) 0 (0) 5 (50) 5 (50)
Cervical adenocarcinoma, n = 6 5 (83.3) 5 (83.3) 0 (0) 0 (0) 3 (50) 0 (0) 3 (50) 3 (50)
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relates to incidence of the infection and disease duration.
Thus infection with a high-risk oncogenic HPV type may
affect the overall prevalence just because of the higher
likelihood of establishment of precancerous lesions and
long-term disease. Accordingly, the lack of follow-up data
(related to viral persistence) to assign a clinical signiﬁcance
to a positive HR HPV test result in the different age
strata is signiﬁcant. Finally, in order to better clarify the
epidemiology of HPV in the general population one needs
to consider the possibility of a positive result being indica-
tive of exposure to a sexual partner’s infection (i.e. coloni-
zation rather than active infection of the participant). In
this regard, epidemiological data for couples [13] or male
populations [14] are important.
In conclusion, high-risk HPV types not covered by the
current HPV vaccines were most prevalent in this cohort
and associated with high-grade cytological changes, raising
questions about the completeness of vaccine efﬁcacy in simi-
lar populations prior to acquiring the infection. However,
the increased prevalence of non-vaccine HPV types may not
relate to a signiﬁcant impact on women because HPV infec-
tion is known to be transient without leading to clinical con-
sequences in the majority of women. Relating screening data
to colposcopic and histological ﬁndings will assist in provid-
ing stronger conclusions. Molecular epidemiology of HPV
infection in our country needs to continue after the imple-
mentation of HPV vaccination in order to assess vaccine efﬁ-
cacy at the population level and guide HPV-based screening
for cervical cancer prevention. Unfortunately, rates of vac-
cine uptake remain low in Greece. Further educational cam-
paign efforts are necessary to promote the use of
prophylactic HPV vaccines. The low rates of HPV types 6
and 11 discovered in this study should not discourage such
efforts. Potential changes in the local molecular epidemiology
of HPV types and their role in cervical carcinogenesis will
need to be studied in detail in the short- and long-term
future.
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